Search

Your search keyword '"Klümpen, Heinz J"' showing total 5 results
Start Over Author "Klümpen, Heinz J"
5 results on '"Klümpen, Heinz J"'

1. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

Author

Öcal, Osman, Schütte, Kerstin, Zech, Christoph J., Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Verslype, Chris, Gebauer, Bernhard, Sengel, Christian, Bargellini, Irene, Iezzi, Roberto, Philipp, Alexander, Berg, Thomas, Klümpen, Heinz J., Benckert, Julia, Pech, Maciej, Gasbarrini, Antonio, Amthauer, Holger, Bartenstein, Peter, Sangro, Bruno, Malfertheiner, Peter, Ricke, Jens, and Seidensticker, Max

Published
2022
Full Text
View/download PDF

2. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial

Author

Surov, Alexey, Wienke, Andreas, Borggrefe, Jan, Hinnerichs, Mattes, Seidensticker, Ricarda, Öcal, Osman, Schütte, Kerstin, Zech, Christoph J., Loewe, Christian, Delden, Otto, Vandecaveye, Vincent, Verslype, Chris, Gebauer, Bernhard, Sengel, Christian, Bargellini, Irene, Iezzi, Roberto, Malfertheiner, Peter, Berg, Thomas, Klümpen, Heinz J., Benckert, Julia, Gasbarrini, Antonio, Amthauer, Holger, Sangro, Bruno, Ricke, Jens, and Seidensticker, Max

Abstract

Our purpose was to assess the impact of muscle quality on overall survival (OS) in patients with advanced HCC. This is a subanalysis of the SORAMIC trial. Overall, 363 patients were included. The SIRT/Sorafenib treatment group comprised 182 patients and the sorafenib group 181 patients. Myosteatosis was defined as skeletal muscle density (SMD) < 41 HU for patients with a body mass index up to 24.9 kg/m2and <33 HU for patients with a body mass index ≥25 kg/m2. Albumin‐gauge score was calculated as follows: serum albumin (g/dL) × SMD (HU). To assess the impact of muscle quality on clinical variables and OS, a Cox regression model was used. Hazard ratios are presented together with 95 % confidence intervals (95 % CI). Kaplan‐Meier curves were used for survival analysis. In the SIRT/sorafenib cohort, low albumin‐gauge score was an independent predictor of worse OS, HR = 1.74, CI 95% (1.16–2.62), p= 0.01. In the sorafenib cohort, muscle quality parameters did not predict OS. In alcohol‐induced HCC (n= 129), myosteatosis independently predicted OS, HR = 1.85, CI 95% (1.10; 3.12), p= 0.02. In viral‐induced HCC (n= 99), parameters of muscle quality did not predict OS. In patients with NASH/Non‐alcoholic fatty liver disease (NAFLD) induced HCC, albumin‐gauge score was a strong independent predictor of worse OS in the subgroup undergoing combined treatment with SIRT and sorafenib, HR = 9.86, CI 95% (1.12; 86.5), p= 0.04. Myosteatosis predicts independently worse OS in patients with alcohol‐induced HCC undergoing combined treatment with SIRT and sorafenib. In patients with NASH/NAFLD induced HCC undergoing treatment with SIRT and sorafenib, albumin‐gauge score predicts independently worse OS. Associations between parameters of muscle quality and OS are different in accordance to the treatment strategy and etiology of HCC. These findings highlight the prognostic potential of skeletal muscle quality in patients with advanced HCC.

Published
2024
Full Text
View/download PDF

3. Prognostic role of radiomics‐based body composition analysis for the 1‐year survival for hepatocellular carcinoma patients

Author

Saalfeld, Sylvia, primary, Kreher, Robert, additional, Hille, Georg, additional, Niemann, Uli, additional, Hinnerichs, Mattes, additional, Öcal, Osman, additional, Schütte, Kerstin, additional, Zech, Christoph J., additional, Loewe, Christian, additional, van Delden, Otto, additional, Vandecaveye, Vincent, additional, Verslype, Chris, additional, Gebauer, Bernhard, additional, Sengel, Christian, additional, Bargellini, Irene, additional, Iezzi, Roberto, additional, Berg, Thomas, additional, Klümpen, Heinz J., additional, Benckert, Julia, additional, Gasbarrini, Antonio, additional, Amthauer, Holger, additional, Sangro, Bruno, additional, Malfertheiner, Peter, additional, Preim, Bernhard, additional, Ricke, Jens, additional, Seidensticker, Max, additional, Pech, Maciej, additional, and Surov, Alexey, additional

Published
2023
Full Text
View/download PDF

4. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

Author

Surov, Alexey, primary, Thormann, Maximilian, additional, Hinnerichs, Mattes, additional, Seidensticker, Max, additional, Seidensticker, Ricarda, additional, Öcal, Osman, additional, Schütte, Kerstin, additional, Zech, Christoph J., additional, Loewe, Christian, additional, van Delden, Otto, additional, Vandecaveye, Vincent, additional, Verslype, Chris, additional, Gebauer, Bernhard, additional, Sengel, Christian, additional, Bargellini, Irene, additional, Iezzi, Roberto, additional, Berg, Thomas, additional, Klümpen, Heinz J., additional, Benckert, Julia, additional, Gasbarrini, Antonio, additional, Amthauer, Holger, additional, Sangro, Bruno, additional, Malfertheiner, Peter, additional, Omari, Jazan, additional, Wienke, Andreas, additional, Ricke, Jens, additional, and Pech, Maciej, additional

Published
2023
Full Text
View/download PDF

5. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

Author

Surov, Alexey, Thormann, Maximilian, Hinnerichs, Matte, Seidensticker, Max, Seidensticker, Ricarda, Öcal, Osman, Schütte, Kerstin, Zech, Christoph J, Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Verslype, Chri, Gebauer, Bernhard, Sengel, Christian, Bargellini, Irene, Iezzi, Roberto, Berg, Thoma, Klümpen, Heinz J, Benckert, Julia, Gasbarrini, Antonio, Amthauer, Holger, Sangro, Bruno, Malfertheiner, Peter, Omari, Jazan, Wienke, Andrea, Ricke, Jen, Pech, Maciej, Iezzi, Roberto (ORCID:0000-0002-2791-481X), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Surov, Alexey, Thormann, Maximilian, Hinnerichs, Matte, Seidensticker, Max, Seidensticker, Ricarda, Öcal, Osman, Schütte, Kerstin, Zech, Christoph J, Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Verslype, Chri, Gebauer, Bernhard, Sengel, Christian, Bargellini, Irene, Iezzi, Roberto, Berg, Thoma, Klümpen, Heinz J, Benckert, Julia, Gasbarrini, Antonio, Amthauer, Holger, Sangro, Bruno, Malfertheiner, Peter, Omari, Jazan, Wienke, Andrea, Ricke, Jen, Pech, Maciej, Iezzi, Roberto (ORCID:0000-0002-2791-481X), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Background:Body composition parameters have been reported to be prognostic factors in patients with oncologic diseases. However, the available data on patients with HCC are conflicting. The aim of this study was to assess the impact of body composition on survival in patients with HCC treated with sorafenib or selective internal radioembolization (SIRT) and sorafenib. Methods:This is an exploratory subanalysis of the prospective, randomized controlled SORAMIC trial. Within the palliative arm of the study, patients were selected if a baseline abdominal CT was available. A broad set of skeletal muscle and adipose tissue parameters were measured at the L3 level. Low skeletal muscle mass (LSMM) and density parameters were defined using published cutoffs. The parameters were correlated with overall survival. Results:Of 424 patients in the palliative study arm, 369 patients were included in the analysis. There were 192 patients in the combined sorafenib/SIRT and 177 patients in the sorafenib group. Median overall survival was 9.9 months for the entire cohort and 10.8 and 9.2 months for the SIRT/sorafenib and sorafenib groups, respectively. There was no relevant association of either body composition parameter with overall survival in either the overall cohort or in the SIRT/sorafenib or sorafenib subgroups. Conclusions:This subanalysis of the prospective SORAMIC trial does not suggest a relevant influence of body composition parameters of survival in patients with advanced HCC. Body composition parameters therefore do not serve in patient allocation in this palliative treatment cohort.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results